Severe acute respiratory syndrome

Avellino Surpasses Two Million COVID-19 Tests in United States

Retrieved on: 
Monday, June 28, 2021
Medical Supplies, Health, Infectious diseases, Genetics, General Health, Biotechnology, Medicine, Health, Infectious diseases, COVID-19 testing, Emergency Use Authorization, COVID-19, Clinical Laboratory Improvement Amendments, Food and Drug Administration, Severe acute respiratory syndrome, Development of COVID-19 tests, DiaSorin

Avellino Lab USA, Inc. (Avellino) today announced that more than two million of its SARS-CoV-2/COVID-19 tests (AvellinoCoV2) have now been performed in the United States.

Key Points: 
  • Avellino Lab USA, Inc. (Avellino) today announced that more than two million of its SARS-CoV-2/COVID-19 tests (AvellinoCoV2) have now been performed in the United States.
  • Avellino was one of the first private companies in the U.S. to receive an Emergency Use Authorization (EUA) from the FDA for AvellinoCoV2 in March 2020.
  • For both the AvellinoCoV2 and AvellinoCoV2-Respiratory tests, Avellino processes the tests in the companys high complexity CLIA-certified lab.
  • The lab can process tens of thousands of tests a day, with further plans to continually increase capacity.

Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission

Retrieved on: 
Thursday, June 24, 2021
Respiratory diseases, Animal diseases, Medical specialties, Occupational safety and health, Atypical pneumonias, COVID-19, Public health, Zoonoses, Severe acute respiratory syndrome

Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall.

Key Points: 
  • Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall.
  • "We are excited that our Brazilian clinical study has now met the minimum FDA-EUA requirements for our submission to secure serial testing approval," expressed Rob Fia, Therma Bright's CEO.
  • Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.
  • Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs.

DeepVerge plc: Microtox® PD claims world first live data alerts of SARS-Cov-2 in wastewater treatment plants

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Public health, COVID-19, Occupational safety and health, Zoonoses, Severe acute respiratory syndrome, Wastewater-based epidemiology

YORK, England, June 24, 2021 /PRNewswire/ -- DeepVerge (LSE: DVRG.L), today announces the successful completion of Phase 3 field trials in which Microtox PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites.

Key Points: 
  • YORK, England, June 24, 2021 /PRNewswire/ -- DeepVerge (LSE: DVRG.L), today announces the successful completion of Phase 3 field trials in which Microtox PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites.
  • "The successful completion of the Phase 3 field trials clearly demonstrates the capability and value of Microtox PD to identify dangerous pathogens, including SARS-CoV-2, in real-time.
  • By establishing a permanent anonymised mass surveillance of wastewater, DeepVerge claims a world first real-time defence against this global pandemic.
  • The installation of Microtox PD wastewater units will enable live data to simultaneously identify the source of COVID-19 cases as well as identify COVID-19 clusters with the ability to indicate the size of each cluster.

Draper Delivers a First by Infecting Lung-on-Chip with Wildtype SARS-CoV-2 Virus

Retrieved on: 
Wednesday, June 23, 2021
Coronaviridae, Medical specialties, Zoonoses, Medicine, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, COVID-19, Severe acute respiratory syndrome, Virus, Viral disease, Coronavirus

"In SARS-CoV-2 research, organ-on-chip is emerging as a powerful method for scientists to assess the potential effects of drugs in humans.

Key Points: 
  • "In SARS-CoV-2 research, organ-on-chip is emerging as a powerful method for scientists to assess the potential effects of drugs in humans.
  • "The door is now open for using naturally circulating viruses to develop and screen therapies for COVID-19 using the best method availableorgan-on-a-chip."
  • In the study, the researchers investigated viral infection kinetics of the SARS-CoV-2 virus in the PREDICT96-ALI platform in a BSL-3 laboratory environment.
  • Results with naturally occurring, or wildtype, virus are more relevant to the infection and replication process that causes disease in humans.

Study finds schools are not at higher risk for COVID-19

Retrieved on: 
Tuesday, June 22, 2021
Coronaviridae, Medicine, Health sciences, Sarbecovirus, Zoonoses, Epidemiology, Infectious diseases, Occupational safety and health, COVID-19, Severe acute respiratory syndrome, Subclinical infection, COVID-19 testing

Even when we account for asymptomatic infection using sensitive blood tests, the risk of SARS-CoV-2 being transmitted in schools overall remains very low, says Dr. David Goldfarb, co-investigator and lead author of the article.

Key Points: 
  • Even when we account for asymptomatic infection using sensitive blood tests, the risk of SARS-CoV-2 being transmitted in schools overall remains very low, says Dr. David Goldfarb, co-investigator and lead author of the article.
  • In this study, school staff reported consistent rates of positive viral tests which are similar to the Vancouver School District1.3 per cent.
  • These results reaffirm that with the protocols we have in place, schools are safe places to teach and learn.
  • This study highlights that COVID-19 in a school setting typically mirrors transmission from family and community contacts.

Bio-Rad Launches Its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit for COVID-19 Wastewater Testing

Retrieved on: 
Monday, June 21, 2021
Health, Infectious diseases, Utilities, Other Health, Energy, Biotechnology, Sarbecovirus, Zoonoses, Animal diseases, Branches of biology, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Real-time polymerase chain reaction, Wastewater-based epidemiology

ddPCR technology is recommended in the Centers for Disease Control and Prevention guidelines (CDC) for wastewater testing, and use of the technology has been published by the Environmental Protection Agency (EPA) as a dependable method to quantify viruses in wastewater.

Key Points: 
  • ddPCR technology is recommended in the Centers for Disease Control and Prevention guidelines (CDC) for wastewater testing, and use of the technology has been published by the Environmental Protection Agency (EPA) as a dependable method to quantify viruses in wastewater.
  • The PREvalenceddPCR SARS-CoV-2 Wastewater Quantification Kit includes all reagents needed to detect the virus in wastewater along with software for automated analysis.
  • Other products include molecular qPCR and ddPCR instruments and assays, antibody tests, quality controls, and ddPCRassays to detect SARS-CoV-2 variants of concern.
  • BIO-RAD, PREVALENCE, DROPLET DIGITAL, DDPCR, QX200, AUTODG and QX ONE are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

PERFORMACIDE® Kills Virus Causing COVID-19 In Just 30 Seconds

Retrieved on: 
Tuesday, June 22, 2021
Sarbecovirus, Respiratory diseases, Animal diseases, Medical specialties, Zoonoses, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Disinfectant

Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.

Key Points: 
  • Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.
  • To prove efficacy, PERFORMACIDE was tested directly against the SARS-CoV-2 (COVID-19) virus.
  • CEO and President, Peter Dornau, commented, "Killing the virus that causes COVID-19 in under a minute will dramatically expand the markets for PERFORMACIDE and its sub-registered brands.
  • Mr. Dornau concluded, "PERFORMACIDE already reduces the many steps involved in a full cleaning routine by eliminating rinsing or wiping again.

Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium

Retrieved on: 
Friday, June 18, 2021
Coronaviridae, Sarbecovirus, Health sciences, Medicine, Zoonoses, Antiviral drugs, COVID-19 pandemic in Russia, Coronavir, Severe acute respiratory syndrome, Brilacidin, COVID-19

The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.

Key Points: 
  • The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.
  • The presentation on Brilacidin will be part of the Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases Breakout Session.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.

Clean Republic Announces SARS-CoV-2 (Covid-19 Virus) 60-Second Kill Claim

Retrieved on: 
Thursday, June 17, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Bactericides, Disinfectant, Hygiene, Animal diseases, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

The announcement comes after testing and resubmission to the EPA and replaces the prior 10-minute kill claim.

Key Points: 
  • The announcement comes after testing and resubmission to the EPA and replaces the prior 10-minute kill claim.
  • At 60 seconds, the Clean Republic Disinfectant + Sanitizer is now one of the fastest acting products on the market for use against SARS-CoV-2.
  • At 60 seconds, Clean Republic Disinfectant + Sanitizer is one of the fastest acting products for use against SARS-CoV-2.
  • "We are proud of the work of our innovations team and this milestone claim from the EPA," said Jake Piccoli, Co-founder and President of Clean Republic.

Two Days Left to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC

Retrieved on: 
Thursday, June 17, 2021
Legal, Professional services, Sarbecovirus, Animal diseases, Health, Directorate-General for Health and Food Safety, Severe acute respiratory syndrome coronavirus 2, European Centre for Disease Prevention and Control, Severe acute respiratory syndrome

Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/ebs .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/ebs .
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
  • or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in Emergent you have until June 18, 2021 to request that the Court appoint you as lead plaintiff.